November 2022

NEUROSCIENCES

VON HIPPEL-LINDAU DISEASE: CLINICAL UPDATE AND NEW DRUG THERAPY

Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome caused by mutations in the VHL gene. These mutations predispose patients to the development of cysts and tumors in several systems and organs, including the central nervous system, retina, kidneys, pancreas, adrenal glands and reproductive organs. VHL is a complex disease that requires specialized treatment from a multidisciplinary team of specialists.
 
In this Better Edge podcast episode, the following experts from the Northwestern Medicine Von Hippel-Lindau Disease Program discuss VHL and the clinical management for this patient population: They share a recent Northwestern Medicine study published in Neuro-Oncology that examined belzutifan, the first approved HIF-2α inhibitor, in VHL-associated tumors.
 
Read the belzutifan study >
Rimas V. Lukas, MD, is an associate professor of Neuro-Oncology at Northwestern Medicine.
Niraj K. Shenoy, MD, PhD, MS, is an associate professor of Hematology and Oncology and of Pathology at Northwestern Medicine.
Brittany M. Szymaniak, PhD, CGC, is an instructor of Urology at Northwestern Medicine.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. 

You May Also Like